12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Olokizumab: Development discontinued

UCB disclosed in its financial results for the first 9 months of 2012 that it will discontinue internal development for olokizumab because data "do not suggest sufficient differentiation potential" vs. Actemra tocilizumab. UCB said it is exploring options...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >